Data alert

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease. The Heart Outcomes Prevention Evaluation (HOPE) trial was stopped early (at 4.5 years) when the ACEI ramipril clearly provided benefit in reducing the risk of CV death, myocardial infarction (MI), and stroke in high-risk patients ages >55 years.1

More recently, the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) assessed the possible vascular and antiatherosclerotic effect of the ACEI perindopril 8 mg in a low-risk population (N = 12,218) of patients ages >18 years with stable CAD but without HF. At 4.2- years, ACEI treatment showed a 20% relative risk reduction in primary outcome (mortality, MI, cardiac arrest) (P = 0.0003).2

HOPE-TOO (HOPE-The Ongoing Outcomes), a 2.6-year extension study of HOPE, evaluated whether the benefits of ACEIs observed in the main HOPE trial are sustained with a longer period of observation and extend to all patients with CV disease.3

Data_Alert.pdf (0.6MB)Data_Alert.pdf (0.6MB)

Extension studies show sustained benefits with ACEI

Download VBWG05-RAAS-Data-Alert.ppt (6 slides - 0.1MB)

Extension studies show sustained benefits with ACEI HOPE-TOO: Study disposition HOPE-TOO: Baseline characteristics in extended follow-up HOPE-TOO: Primary outcome (CV death, MI, stroke) HOPE-TOO: Additional risk reduction in major CV events and new-onset diabetes Benefit of treatment with ACEI

For additional information on this study

References are listed at the end of the Data Alert.


Related at vwbg.org

Data and Commentary:The HOPE Study

Effects of angiotensin-converting enzyme inhibition on cardiovascular events in high-risk patients

The Heart Outcomes Prevention Evaluation Study Investigators.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.
More related